{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "OFIX",
  "name": "Orthofix Medical Inc.",
  "url": "https://orbyd.app/dossiers/OFIX/",
  "json_url": "https://orbyd.app/dossiers/OFIX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Reimbursement-reversal re-rate has already been spent: CMS restored pre-May-18 bone-growth-stimulator rates (reported 2026-07-02) and the 2026-08-05 Q2 print beat on both lines with FY26 guidance raised to $845–855M / $95–98M adj EBITDA — and the stock fell ~10%, closing $10.28 on 2026-08-07, -36.7% off its $16.23 high. Nothing dated until the ~November Q3 print.",
  "invalidation_trigger": "A weekly close below $9.80 (loses the $10 handle that survived the 2026-08-05 post-print sell-off, leaving the July CMS-reversal advance without structural support); secondary, a ~2026-11-04 Q3 print that again shows negative free cash flow and adjusted EBITDA below the year-ago $20.6M.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "oil-energy-geopolitical",
    "small-cap-value-rotation"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Medicare rates on HCPCS E0747/E0748/E0760 set a material share of Therapeutic Solutions revenue and can change at CMS discretion — the 2026-05-18 cut took effect with days of notice.",
    "The 2026-05-21 8-K stated the company does not expect positive free cash flow for full-year 2026; six-month FCF was $(47.1)M.",
    "Three-year financial targets were withdrawn on 2026-05-21 as 'no longer applicable' and were not reinstated with the 2026-08-05 FY26 guidance raise.",
    "Balance sheet at Q2 2026: cash and equivalents $103.8M against $221.6M long-term debt — refinancing terms are a standing variable for a loss-making quarter run-rate.",
    "FDA moved non-invasive bone growth stimulators from Class III to Class II on 2026-04-16, lowering the entry barrier for 510(k) competitors in the franchise."
  ],
  "body_markdown": "## Current Thesis\nThe leg on offer was a reimbursement-reversal re-rate: CMS cut average Medicare reimbursement on non-invasive bone growth stimulators (HCPCS E0747/E0748/E0760) by roughly 10% effective 2026-05-18, Orthofix pulled guidance down and scrapped its three-year targets in a 2026-05-21 8-K, and then CMS reversed — pre-May-18 rates restored, reported 2026-07-02. The confirmation arrived on 2026-08-05: Q2 net sales $210.9M beat the $209.277M consensus, adjusted EPS $0.07 against a $(0.41) estimate, FY2026 sales guidance up to $845–855M from $838–848M and adjusted EBITDA up to $95–98M from $90–93M. The market sold it. Seeking Alpha's 2026-08-06 write-up put the reaction near -10%, and the 2026-08-07 close of $10.28 sits 36.7% below the $16.23 52-week high. The bullish catalyst has been spent and paid nothing; what remains is an unprofitable, cash-consuming turnaround with no dated company event until the Q3 print in November.\n\n## Bull Case\n- **The overhang is legally resolved, not merely deferred.** CMS restored pre-May-18 reimbursement rates for non-invasive bone growth stimulators (reported 2026-07-02), reversing the ~10% average decline the 2026-05-21 8-K identified as the reason guidance was cut.\n- **Guidance moved up in both lines on 2026-08-05.** FY2026 net sales $845–855M (prior $838–848M); adjusted EBITDA $95–98M (prior $90–93M), which the company framed as ~80bps of margin expansion versus 2025.\n- **Q2 2026 cleared consensus on both lines** — net sales $210.9M vs $209.277M estimate, adjusted EPS $0.07 vs $(0.41) estimate — with reported sales +4% and pro forma constant-currency growth of ~5%.\n- **Growth is concentrated where the reimbursement risk is not.** Global Limb Reconstruction did $37.7M, +13.2% reported and +11.0% constant currency; the release cites double-digit constant-currency growth in Global Spine Fixation as well. Therapeutic Solutions (the former Bone Growth Therapies franchise) was $64.2M, +2.5%.\n- **Published targets sit far above the tape.** stockanalysis.com showed a 5-analyst average target of $21.50 with a $16–$24 range as of 2026-08-08 — a screen that does not yet reflect Stifel's post-print cut to $13 from $15 (Buy maintained, Thomas Stephan, ~2026-08-06). Either the sell side marks down further or the gap to a $10.28 close is real.\n\n## Bear Case\n- **The beat-and-raise was distributed into.** A confirmed reimbursement reversal plus a raised EBITDA guide produced a down day of roughly 10% (Seeking Alpha, 2026-08-06). When a narrative's own confirming event is sold, the marginal buyer it was supposed to attract is not there.\n- **Profitability went the wrong way on higher sales.** Q2 2026 net loss $(15.8)M against $(14.1)M in Q2 2025; adjusted EBITDA $20.1M against $20.6M — a lower absolute EBITDA on sales up 4%.\n- **Cash burn is the live problem.** Six-month free cash flow $(47.1)M versus $(20.6)M a year earlier. The 2026-05-21 8-K stated the company does not expect positive free cash flow for full-year 2026. Cash and equivalents $103.8M against long-term debt of $221.6M at quarter-end. Q2 call coverage attributes part of the drag to a European distributor arrangement pushing inventory outflows into 2026 with receipts landing in 2027.\n- **The structural door CMS walked through is still open.** FDA reclassified non-invasive bone growth stimulators from Class III to Class II on 2026-04-16 — the action that preceded the rate cut. Class II lowers the barrier for 510(k) competitors and leaves the pricing basis exposed to future CMS review.\n- **Multi-year framing is gone.** The three-year financial targets withdrawn on 2026-05-21 as \"no longer applicable\" were not restored alongside the FY2026 raise; the 2026-08-05 update covers this fiscal year only.\n- **Commercial productivity is the acknowledged soft spot.** Q2 call coverage flags smaller U.S. spine distributors as a persistent weakness expected to continue through 2026, offsetting strength at the largest distributors.\n\n## Setup & Price Structure\n- Last completed daily close $10.28 (2026-08-07). 52-week high $16.23; distance from high -36.7%. Three-month return -11.8%. RSI(14) 38.0 — lower half of range, no oversold extreme.\n- The -11.8% three-month figure spans the 2026-05-18/05-21 reimbursement shock, the July recovery on the CMS reversal, and the post-print decline. Price recovered a portion of the May damage and gave a chunk back inside two sessions after 2026-08-05.\n- Structurally, the $10 handle survived the post-print sell-off. That is the only defended reference the recent tape offers; below it the July reversal rally has no visible shelf.\n- **Life-cycle: DEAD.** Dating it: the narrative's resolving events were 2026-07-02 (CMS restoration) and 2026-08-05 (beat, raise, both lines). Both are now behind the tape, and price is lower after each. A narrative that has already printed its best available news and trades 36.7% under its 52-week high is not accelerating and is not maturing — its bid failed on confirmation.\n- **Crowding and positioning observables.** Retail-facing coverage clustered tightly around the CMS reversal: Benzinga gainer lists on 2026-07-06, a 2026-07-21 \"small caps on fire\" round-up, then mover lists again pre- and after-market on 2026-08-05. Price is below trend rather than extended above a rising average, so there is no distance-from-average stretch to unwind. The earnings binary has passed (2026-08-05), removing event risk and event support alike. No insider transactions or equity issuance appear in the recent filing record reviewed for this note — absence in that record is not proof of absence.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-10-01 (est.)** — CMS quarterly DMEPOS fee-schedule update. Whether the restored E0747/E0748/E0760 rates carry forward unchanged is the single largest exogenous variable for Therapeutic Solutions revenue.\n- **~2026-11-04 (est.)** — Q3 2026 results. First test of whether the raised $845–855M / $95–98M ranges hold with a full quarter of restored reimbursement, and whether free cash flow inflects off the $(47.1)M six-month figure.\n- **~2026-02 (est., Q4/FY26 print)** — the window in which reinstated multi-year targets, if they return at all, would appear.\n\n## Elapsed catalysts\n\n- **No confirmed company-specific catalyst falls inside the 30 days from 2026-08-08.** The Q2 print (2026-08-05) and the CMS restoration (reported 2026-07-02) are both behind. *(passed 1d ago)*\n\n## What Would Change Our Mind\nThe failed-catalyst read breaks if the tape stops treating good news as an exit. Concretely: a Q3 print (~2026-11-04, est.) that shows positive quarterly free cash flow and adjusted EBITDA above the year-ago $20.6M on higher sales would contradict the \"growth without profit\" objection that killed the August reaction — the argument then becomes a genuine margin inflection rather than a reimbursement rebate. Reinstatement of withdrawn multi-year targets would do the same work. On the tape, the constructive-repair case requires the $10 area to function as a base: a weekly close below $9.80 removes the handle that survived the post-print sell-off and leaves the entire July CMS-reversal advance without structural support, which would confirm the narrative as broken rather than merely unrewarded. In the other direction, a weekly close back above the pre-print level with expanding volume, ahead of any new CMS action, would argue the August reaction was liquidation rather than a verdict.\n\n## Correlation Notes\n- **Reimbursement policy is the dominant shared factor, not surgical volumes.** Any issuer with material revenue in HCPCS E0747/E0748/E0760 — Bioventus is the closest listed comparison on non-invasive bone growth stimulators — moves on the same CMS decisions that drove OFIX between 2026-05-18 and 2026-07-02. That correlation is regulatory and steps discretely; it does not track medtech beta.\n- **Spine and extremities peers** (Globus Medical, Alphatec, and the large-cap ortho complex) share procedure-volume and distributor-productivity exposure. Orthofix's specific problem — smaller U.S. spine distributor productivity, per Q2 call coverage — is company-level and would not show up in peer prints.\n- **FX is a visible wedge, not noise.** Global Limb Reconstruction grew 13.2% reported versus 11.0% constant currency in Q2 2026; a reversal in the dollar removes that reported-growth cushion.\n- **Small-cap liquidity beta applies.** The name appeared repeatedly in July retail gainer round-ups, so Russell 2000-level risk appetite affects the marginal bid independently of anything Orthofix reports.",
  "first_seen": "2026-07-31",
  "last_analyzed": "2026-08-08T09:44:05+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}